Sat.Jul 23, 2022 - Fri.Jul 29, 2022

'Flat is the new up': After biotech correction, venture investors turn to safer bets

Bio Pharma Dive

New companies are being built more carefully and platform technologies are less in vouge as the downturn's effects ripple through the private sector

278
278

Amazon’s big gamble

World of DTC Marketing

Quick Read: Amazon will dramatically expand its healthcare reach with its planned $3.9 billion acquisition of One Medical, a primary care provider with 188 offices in 25 markets nationwide but are they making a strategic move or a mistake?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalizing the Cancer Patient Journey

Pharma Marketing Network

In the first two weeks after a cancer diagnosis, there are likely dozens of doctor’s visits, tests, consultations, and decision points.

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

According to GlobalData’s recent Niemann-Pick Type C (NPC): Opportunity Analysis and Forecast to 2031 report, the NPC market is expected to see significant growth during 2021–31.

Gene 98

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

Versant partners with AbCellera to arm startups with better antibodies

Bio Pharma Dive

The companies pitch their collaboration as a way to give young drugmakers backed by Versant a head start. “Our business is advanced by great ideas coming into the funnel,” said AbCellera’s CEO

The continued shame of pharma

World of DTC Marketing

Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses.

More Trending

Do generics producers have what it takes to tackle complex and specialty drugs?

Pharmaceutical Technology

With decreasing margins on the horizon, pharma manufacturers have long shown an interest in specialty generics, which is only expected to rise in the future.

FDA, in another test of its flexibility, agrees to review Biogen's closely watched ALS drug

Bio Pharma Dive

Known as tofersen, the drug failed in the main study being used to support its approval. But an apparent effect on a protein of interest in ALS research has Biogen convinced the treatment will pass muster with regulators

PBMs and insurers want your prescription money

World of DTC Marketing

A federal appeals court rejected Pfizer’s challenge to a U.S. anti-kickback law that the drugmaker said prevented it from helping heart failure patients, many with low incomes, afford the medicine that costs $225,000 annually.

Omicron BA.5 Surge: 5 Ways to Stay Safe

NY Times

The BA.5 surge is a reminder that we need to take precautions to avoid illness, slow the relentless cycle of new variants and minimize the disruption to our daily lives.

Drugs 82

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

FDA accepts to review ImmunityBio’s BLA for bladder cancer treatment

Pharmaceutical Technology

The Food and Drug Administration (FDA) has acc epted to review ImmunityBio’s Biologics License Application (BLA) for N-803 to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients with or without Ta or T1 disease.

Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves

Bio Pharma Dive

The company plans to ready a booster shot by the fall that targets the BA.4 and BA.5 strains that are currently most prevalent in the U.S. and other countries

Sales 254

AstraZeneca reports sales drop for Evusheld. Why is the variant-busting COVID med underachieving?

Fierce Pharma

AstraZeneca reports sales drop for Evusheld. Why is the variant-busting COVID med underachieving? kdunleavy. Fri, 07/29/2022 - 10:10

Sales 114

After Roe, Pregnant Women With Cancer Diagnoses May Face Wrenching Choices

NY Times

Urgent questions arise about how care of pregnant women with cancer will change in states where women are unable to terminate pregnancies. Pregnancy and Childbirth Abortion Breast Cancer Cancer Drugs (Pharmaceuticals

Drugs 82

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Can a nasal spray tackle agitation in autism?

Pharmaceutical Technology

The rate at which children are being identified with autism spectrum disorder (ASD) has tripled in the past two decades. While the prevalence was 1 in 150 children in 2000, it reached the rate of 1 in 44 in 2018, in the US, according to the Centers for Disease Control and Prevention.

AstraZeneca, Daiichi breast cancer drug set for speedy FDA review

Bio Pharma Dive

The agency agreed to quickly assess the companies’ drug Enhertu for “HER2 low” metastatic breast cancer, an indication for which it could become the first targeted treatment option

Drugs 256

Work and Cancer: How to Get Help Through “Reasonable Accommodations”

Triage Cancer

Today, we celebrate the 32 nd anniversary of the Americans with Disabilities Act (ADA), signed into law by President George H.W. Bush on July 26, 1990. The ADA is a federal law that protects eligible individuals with disabilities against discrimination.

HR 80

Nothing to Seagen here: Merck remains mum on merger

Fierce Pharma

Nothing to Seagen here: Merck remains mum on merger. kdunleavy. Thu, 07/28/2022 - 10:24

112
112

EMA task force begins review of Veru’s sabizabulin for Covid-19

Pharmaceutical Technology

The Emergency Task Force (ETF) of the European Medicines Agency (EMA) has commenced the review of Veru’s sabizabulin to treat hospitalised Covid-19 patients at increased acute respiratory distress syndrome (ARDS) risk.

US secures updated COVID boosters in $1.7B deal with Moderna

Bio Pharma Dive

Health officials are gearing up for a fall vaccination campaign and aim to deploy shots modified to better match circulating omicron subvariants

The continued search for a cure to HIV

pharmaphorum

Not very long ago, contracting HIV was an effective death sentence; today, there are treatments that allow the condition to be managed but not eradicated.

Fentanyl From the Government? A Vancouver Experiment Aims to Stop Overdoses

NY Times

A city on the forefront of harm reduction has taken the concept to a new level in an effort to address the growing toxicity of street drugs.

Pfizer reports 53% operational growth in Q2 2022 revenues

Pharmaceutical Technology

Pfizer has reported a 53% operational growth in revenues to $27.7bn in the second quarter (Q2) of 2022 compared to $18.9bn in the same quarter last year. The rise in revenues was chiefly driven by robust contributions from Covid-19 therapies Paxlovid and Comirnaty.

Sales 83

Epigenetic editing: a tunable CRISPR alternative

Bio Pharma Dive

Three startups have recently emerged with plans to edit the epigenome rather than DNA directly. Here’s why that matters and what they aim to do

DNA 250

Macmillan alliance will provide digital health apps to cancer patients

pharmaphorum

Newly diagnosed cancer patients across the UK will get free access to digital mental health therapies, thanks to a new partnership between Macmillan Cancer Support and Big Health.

Trials 107

Human element important for decentralized trial advancement

Outsourcing Pharma

During the Decentralized Trial Technology event, experts from CVS Health, University of Chicago, and ACRP shared insight on what can increase DCT success. Clinical Development

Trials 103

Schizophrenia trials continue to test drug candidates as Covid-19 pandemic continues

Pharmaceutical Technology

Schizophrenia Awareness Day, marked on 25 July, is a national observance that aims to raise awareness about this mental illness. Schizophrenia is a chronic brain disorder that affects a person’s ability to function, such as thinking and feeling.

Seagen, Astellas claim positive results in study key to cancer drug's success

Bio Pharma Dive

The mid-stage trial tested the companies’ drug Padcev with Merck’s Keytruda in first-line bladder cancer. The data are reportedly a factor in Merck’s talks with Seagen over a potential buyout

Trials 242

Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2

pharmaphorum

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants.

Large-scale screen shows how cancer cells respond to drug delivery nanoparticles

Fierce Pharma

Large-scale screen shows how cancer cells respond to drug delivery nanoparticles. ntaylor. Tue, 07/26/2022 - 11:21

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. Their use of regRNA technology provides a unique approach to treating rare conditions like urea cycle disorders.

RNA 82

Sarepta to ask FDA for accelerated approval of Duchenne gene therapy

Bio Pharma Dive

After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing

Philips on designing innovation and cultivating partnerships – part one

pharmaphorum

Sachin Grover, lead of solutions vertical at Philips India, tells me about the company’s innovations during India’s COVID outbreak and how they’ve led to increased healthcare access in the region.

Merck dodged billions in US taxes in offshoring Keytruda profits, Senate Democrats contend

Fierce Pharma

Merck dodged billions in US taxes in offshoring Keytruda profits, Senate Democrats contend. fkansteiner. Thu, 07/28/2022 - 07:04

94